Literature DB >> 1381438

Characterization of HIV isolates arising after prolonged zidovudine therapy.

D L Mayers1, F E McCutchan, E E Sanders-Buell, L I Merritt, S Dilworth, A K Fowler, C A Marks, N M Ruiz, D D Richman, C R Roberts.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) was isolated from five patients with late-stage disease treated with zidovudine (ZDV) for more than 1 year. Peripheral blood mononuclear cells (PBMCs) were used for all virus isolations and to assay for drug resistance. The isolates exhibited a 10- to 100-fold decrease in ZDV susceptibility compared to pretreatment isolates. Multiple clones of a 618 bp segment of the HIV reverse transcriptase gene encompassing codons 60-250 were sequenced for each isolate. The association of alterations at codons Asp67----Asn, Lys70----Arg, Thr215----Phe or Tyr, and Lys219----Gln with ZDV resistance has been previously noted (ref. 5). In this study, the most frequent alterations was Thr215----Tyr although genotypic mixtures of Thr/Tyr and Phe/Tyr were also observed. One isolate with a Tyr215 alteration and unaltered codons at 67, 70, and 219 had high-level ZDV resistance. Alterations at codons 67, 70, and 219 did not appear to increase resistance when seen in combination with Tyr215. Virus isolates obtained from each patient by cultivation with either 0 or 4 microM ZDV were compared and found to have similar alterations at codons 67, 70, 215, and 219, although one instance of apparent in vitro selection for Tyr215 over Phe215 was observed. Assays using PBMCs for virus propagation will permit susceptibility testing of HIV isolates from most patients on antiretroviral drugs to investigate the clinical significance of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381438

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  25 in total

Review 1.  Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology.

Authors:  I M Rouzine; A Rodrigo; J M Coffin
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

4.  High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.

Authors:  T Imamichi; T Sinha; H Imamichi; Y M Zhang; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.

Authors:  S D Kemp; C Shi; S Bloor; P R Harrigan; J W Mellors; B A Larder
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors:  J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

7.  Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.

Authors:  D L Mayers; A J Japour; J M Arduino; S M Hammer; R Reichman; K F Wagner; R Chung; J Lane; C S Crumpacker; G X McLeod
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 8.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

9.  Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.

Authors:  J E Fitzgibbon; A E Farnham; S J Sperber; H Kim; D T Dubin
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.

Authors:  S D Malley; J M Grange; F Hamedi-Sangsari; J R Vila
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.